A recent report into diabetes drugs indicates that patients with diabetes who use rosiglitazone could face a lower risk of developing diabetic retinopathy . Furthermore, people taking this drug may also be less likely to experience lower visual acuity, the report shows.
Diabetic retinopathy is one of the complications of diabetes, and refers to the formation of tiny blood vessels in the eye. This damages the vision, in some cases quite severely, and there are very few effective treatments for it.
A research team at the University of California Jules Stein Eye Institute surveyed people with diabetes who took rosiglitazone. The study authors reportedly commented:
“However, because this study does not rigorously prove that rosiglitazone either reduces the incidence of proliferative diabetic retinopathy or prevents loss of visual acuity, and because there may be adverse effects from therapy, rosiglitazone treatment of patients with diabetes specifically to reduce these ophthalmic complications is not advocated at this time.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…